Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Low-grade Glioma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × tovorafenib × CNS × Clear all
NCT05465174 2026-04-23

PNOC029

University of California, San Francisco

Phase 2 Recruiting
57 enrolled
CNS

Craniopharyngioma

NCT07206849 2026-04-08

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Nationwide Children's Hospital

Phase 2 Not yet recruiting
79 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Glioma

NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04775485 2025-04-10

FIREFLY-1

Day One Biopharmaceuticals, Inc.

Phase 2 Recruiting
141 enrolled 1 FDA
CNSOther solid neoplasm

Low-grade Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡